CNS
Cohen & Steers, Inc. · Financial Services
63.90
1.75%(+1.10)
Prev. Close71.50
11.89%(+7.60)
Pre-marketLast Updated: — ET
52W L: $58.3952W H: $83.99
Cohen & Steers, Inc. · Financial Services
Aggarwal Reena
director
440 SH @ $0.00
2026-04-01
THISSEN KAREN WILSON
director
440 SH @ $0.00
2026-04-01
Smith Dasha
director
440 SH @ $0.00
2026-04-01
Connor Frank T
director
440 SH @ $0.00
2026-04-01
Dolly Lisa
director
440 SH @ $0.00
2026-04-01
COHEN MARTIN
director, 10 percent owner:
440 SH @ $0.00
2026-04-01
Villani Edmond D
director
433 SH @ $0.00
2026-04-03
Villani Edmond D
director
440 SH @ $0.00
2026-04-01
NEW YORK, April 8, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced that it expects to release first quarter 2026 results after the market closes on Thursday, April 16, 2026. The earnings release and accompanying earnings presentation will be available on the company's website at www.cohenandsteers.com under "Company—Investor Relations—Earnings Archive.
NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced peer-reviewed Phase 2a results (NCT05660642) in CNS Drugs demonstrating that a single intranasal dose of BPL-003 (mebufotenin benzoate), which holds FDA Breakthrough Therapy Designation, achieved rapid and sustained reductions in MADRS scores from baseline in participants with treatment-resistant depression (TRD) who remained on stable SSRI therapy throughout the study (n=12). A 66.7% antidepressant response rate (≥50% reduction from baseline MADRS score) was observed at Day 2 in both the 10 mg (n=6) and 12 mg (n=6) cohorts, with 83% (5/6) of participants in the 10 mg cohort and 66.7% (4/6) of participants in the 12 mg cohort maintaining a response at Week 12. BPL-003 was generally well tolerated with no serious adverse events reported, and participants achieved a mean discharge approximately 100 minutes post-dose. Phase 3 studies are on track to initiate in Q2 2026 following recent FDA End-of-Phase 2 (EOP2) alignment.
I present an expanded Top 25 High-Yield dividend stock watchlist for April 2026, targeting quality, value, and long-term return potential. The selected stocks average a 3.86% dividend yield and a projected 19.07% future CAGR, with ~34% average undervaluation per dividend yield theory. Subsets highlight opportunities in high yield (e.g., Campbell's at 7%), fast dividend growth (Autoliv, 38.15%), and deep value (Nike, -63.81% undervalued).
NEW YORK, March 30, 2026 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers REIT and Preferred and Income Fund, Inc. (NYSE: RNP) (the "Fund") with information regarding the sources of the distribution to be paid on March 31, 2026 and cumulative distributions paid fiscal year-to-date. In December 2017, the Fund implemented a managed distribution policy in accordance with exemptive relief issued by the Securities and Exchange Commission.
NEW YORK, March 30, 2026 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers Quality Income Realty Fund, Inc. (NYSE: RQI) (the "Fund") with information regarding the sources of the distribution to be paid on March 31, 2026 and cumulative distributions paid fiscal year-to-date. In December 2012, the Fund implemented a managed distribution policy in accordance with exemptive relief issued by the Securities and Exchange Commission.
NEW YORK, March 30, 2026 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers Closed-End Opportunity Fund, Inc. (NYSE: FOF) (the "Fund") with information regarding the sources of the distribution to be paid on March 31, 2026 and cumulative distributions paid fiscal year-to-date. In December 2021, the Fund implemented a managed distribution policy in accordance with exemptive relief issued by the Securities and Exchange Commission.